Clinical Trial Update: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating N-803 plus tislelizumab or prior failed immune checkpoint inhibitor with docetaxel vs docetaxel alone in advanced/metastatic non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• N-803
• Tislelizumab (tislelizumab)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NSCLC Stage IV | Phase 3 | Status: RECRUITING